



Revision date: 17-Aug-2016

Version: 1.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Naloxone Hydrochloride Injection, USP (Hospira Inc.)

Trade Name:

Naloxone Hydrochloride Injection

Chemical Family:

Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use:

Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045

1-800-879-3477

Hospira UK Limited

Horizon **Honey Lane** Hurley

Maidenhead, SL6 6RJ **United Kingdom**

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail:

pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Not classified as hazardous

Label Elements

Signal Word:

Not Classified

Hazard Statements:

Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

Page 2 of 9

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016 Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**
Naloxone hydrochloride	357-08-4	206-611-0	Not Listed	0.04

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	*
Propylparaben	94-13-3	202-307-7	Not Listed	*
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*

Additional Information:

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical

attention.

Skin Contact:

Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure:

Identification and/or Section 11 - Toxicological Information.

Medical Conditions

None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:

None

5. FIRE FIGHTING MEASURES

Extinguishing Media:

As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016 Version: 1.0

Hazardous Combustion

Products:

Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

Page 3 of 9

area thoroughly.

Additional Consideration for

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:

Store as directed by product packaging.

Specific end use(s):

Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

HYDROCHLORIC ACID

 ACGIH Ceiling Threshold Limit:
 2 ppm

 Australia PEAK
 5 ppm

 7.5 mg/m³
 7.5 mg/m³

 Austria OEL - MAKs
 5 ppm

 8 mg/m³
 8 ppm

 Belgium OEL - TWA
 5 ppm

8 mg/m³ **Bulgaria OEL - TWA**5 ppm

8.0 mg/m³

8.0 mg/m

Cyprus OEL - TWA

5 ppm
8 mg/m³

Czech Republic OEL - TWA

8 mg/m³

Page 4 of 9

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016 Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

O. EXPOSURE CONTROLS / PERSONAL PROTI	ECTION
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³
Greece OEL - TWA	5 ppm
	7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm
	8 mg/m ³
Italy OEL - TWA	5 ppm
•	8 mg/m ³
Japan - OELs - Ceilings	2 ppm
Control Report of Statement Control Control	3.0 mg/m^3
Latvia OEL - TWA	5 ppm
	8 mg/m ³
Lithuania OEL - TWA	5 ppm
	8 mg/m ³
Luxembourg OEL - TWA	5 ppm
	8 mg/m ³
Malta OEL - TWA	5 ppm
	8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm
	8 mg/m ³
Romania OEL - TWA	5 ppm
	8 mg/m ³
Slovakia OEL - TWA	5 ppm
	8.0 mg/m ³
Slovenia OEL - TWA	5 ppm
	8 mg/m ³
Spain OEL - TWA	5 ppm
	7.6 mg/m ³
Switzerland OEL -TWAs	2 ppm
	3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³
SODIUM CHLORIDE	
Latvia OEL - TWA	5 mg/m ³
	5 1119/111

Lithuania OEL - TWA 5 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Naloxone hydrochloride

Pfizer Occupational Exposure OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³) **Band (OEB):**

Exposure Controls

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016 Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective

Equipment:

Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Solution

Color:

Colorless

Odor:

No data available.

Odor Threshold:

No data available.

Page 5 of 9

Molecular Formula:

Mixture

Molecular Weight:

Mixture

Solvent Solubility: Water Solubility:

Boiling Point (°C):

No data available No data available

pH:

3.0-6.5

Melting/Freezing Point (°C):

No data available No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

HYDROCHLORIC ACID

No data available

SODIUM CHLORIDE

No data available

Methylparaben

No data available

Propylparaben

No data available

Water for Injection

No data available

Naloxone hydrochloride

No data available

Decomposition Temperature (°C):

No data available.

Evaporation Rate (Gram/s):

No data available No data available

Vapor Pressure (kPa):

No data available

Vapor Density (g/ml): Relative Density:

No data available No data available

Viscosity:

Flammablity:

Autoignition Temperature (Solid) (°C):

No data available

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016 Version: 1.0

Flammability (Solids): Flash Point (Liquid) (°C): No data available No data available No data available

Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.):

No data available

Page 6 of 9

10. STABILITY AND REACTIVITY

Reactivity:

No data available

Chemical Stability:

Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties:

None

Conditions to Avoid: Incompatible Materials:

Not determined

Hazardous Decomposition

As a precautionary measure, keep away from strong oxidizers Thermal decomposition products may include carbon monoxide, carbon dioxide, oxides of

Products:

nitrogen and hydrogen chloride.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual

ingredients.

Known Clinical Effects:

The most common adverse effects seen during clinical use of this drug include headache, sweating, nausea, decrease in blood pressure (hypotension), increase in blood pressure (hypertension), shortness of breath (dyspnea), increased heart rate (tachycardia), irritability,

anxiety, inability to concentrate, lack of appetite.

Acute Toxicity: (Species, Route, End Point, Dose)

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3g/kg Mouse Oral LD 50 4g/kg Rabbit Dermal LD 50 > 10g/kg

Naloxone hydrochloride

Rat Oral LD50 > 1000 mg/kg Mouse Oral LD50 > 1000mg/kg Rat Intravenous LD50 107mg/kg Mouse Intravenous LD50 90mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild Eye Irritation Rabbit Mild

Page 7 of 9

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016 Version: 1.0

11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Naloxone hydrochloride

Embryo / Fetal Development Rat No route specified8 times human dose NOAEL Not teratogenic Embryo / Fetal Development Mouse No route specified 4 times human dose NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vivo Micronucleus Rat Negative

Naloxone hydrochloride

Bacterial Mutagenicity (Ames) Positive

In Vitro Chromosome Aberration Human Lymphocytes Positive Mammalian Cell Mutagenicity HGPRT Hamster Negative In Vivo Chromosome Aberration Rat Bone Marrow Negative

In Vivo Micronucleus Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016

Page 8 of 9 Version: 1.0

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Methylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances	5000 lb
and their Reportable Quantities:	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous	5000 lb

Substances EPCRA RQs

California Proposition 65 Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 5 for Drugs and Poisons: Schedule 6 **EU EINECS/ELINCS List** 231-595-7

Propylparaben

CERCLA/SARA 313 Emission reporting Not Listed California Proposition 65 Not Listed

Page 9 of 9

Material Name: Naloxone Hydrochloride Injection, USP

(Hospira Inc.)

Revision date: 17-Aug-2016 Version: 1.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

202-307-7

Naloxone hydrochloride

CERCLA/SARA 313 Emission reporting

California Proposition 65

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

206-611-0

SODIUM CHLORIDE

CERCLA/SARA 313 Emission reporting

California Proposition 65
Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed
Not Listed
Present
231-598-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 17-Aug-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet